FLT3 and acute myeloid leukemia: The CR rate after one cycle did not differ between the two treatment groups in patients with AML bearing IDH1/2 (90.9% vs 70%, p = 0.293) or FLT3‐TKD mutations (87.5% vs 66.7%, p = 0.538).